Meridian Small Cap Growth Fund on Definium Therapeutics, Inc.

Meridian owns Definium Therapeutics for what it sees as a potentially best-in-class rapid-acting, single-dose therapy profile in large underserved mental-health markets. Positive topline results from a pivotal Phase 3 major-depressive-disorder study exceeded the efficacy bar investors had set and showed durable treatment effects with high remission rates versus placebo. The result materially de-risked the program and shifted attention to the upcoming generalized-anxiety-disorder readout as the next major catalyst.